This study is looking at whether a procedure called transcatheter edge-to-edge repair (TEER) can help people experiencing cardiogenic shock (a severe form of heart failure where your heart can't pump enough blood). TEER is a way to fix a leaky heart valve (mitral regurgitation) without open-heart surgery. Currently, people with cardiogenic shock receive medical treatment in an intensive care unit. This study will compare TEER to standard medical treatment. To join, you must be at least 18 years old and have cardiogenic shock that requires ongoing support from medications or breathing machines. The study aims to see if TEER improves overall outcomes during hospitalization. The current recruitment status is unclear, but the study plans to enroll 144 participants.

Study design

This is a multicenter, open-label, randomized-controlled trial with two groups: one receiving medical therapy and one receiving TEER. It plans to enroll 144 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed through the duration of hospitalization, generally up to 12 weeks following admission.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.